Initial Visit:Ā
CBC, CMP
Follow-Up:Ā
CMP
For weight management, GLP-1s are typically used for 6 to 12 months. Since weight regain is common after stopping, many choose to continue GLP-1s indefinitely on a lower maintenance dose to keep weight off.
It is crucial to pair the medication with a healthy diet and lifestyle to support long-term success, even if you stay on a maintenance dose.
Initial weight loss is noticeable within the first few weeks; most significant changes happen after 3ā6 months.
Nausea, vomiting, diarrhea, constipation, bloating, stomach pain. Rare risks include pancreatitis or gallbladder inflammation.
Compounded drug products are not approved or evaluated for safety, effectiveness, or quality by the FDA. Prescription required.
Prescription products require an online consultation with a health care provider who will determine if a prescription is appropriate. FSA/HSA eligibility and coverage varies by plan provider
OzempicĀ® (semaglutide), WegovyĀ® (semaglutide), MounjaroĀ® (tirzepatide), and ZepboundĀ® (tirzepatide) are not compounded. OzempicĀ®, and MounjaroĀ® are FDA-approved for type 2 diabetes treatment but may be prescribed off-label for weight loss at a healthcare provider’s discretion. WegovyĀ® and ZepboundĀ® are FDA-approved for weight loss. OzempicĀ® and WegovyĀ® are the registered trademarks of Novo Nordisk A/S. MounjaroĀ® and ZepboundĀ® are registered trademarks of Eli Lilly and Company. The Rainbow Bandaid, PLLC is not affiliated or endorsed by Novo Nordisk A/S or Eli Lilly and Company.